South Korean Pitavastatin Heart Failure Study (SAPHIRE)

This study has been completed.
Information provided by (Responsible Party):
JW Pharmaceutical Identifier:
First received: June 17, 2008
Last updated: May 12, 2014
Last verified: May 2014
We want to evaluate the utility of statins on heart function according to potency. Patients with chronic ischemic heart failure are administered pitavastatin 4mg or pravastatin 10mg for 52 weeks. Then we evaluate the effect of pitavastatin and pravastatin primarily on rate of hospitalization for cardiovascular cause and lipid profile secondarily biomarker, echocardiography parameter, 6-minute walk, change of NYHA class distribution, cardiovascular mortality.

Condition Intervention Phase
Chronic Heart Failure
Drug: pitavastatin
Drug: pravastatin
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Prospective, Randomized, Two Group Comparison Study to Evaluate the Effect of Statin on Heart Function in Patients With Chronic Ischemic Heart Failure.

Resource links provided by NLM:

Further study details as provided by JW Pharmaceutical:

Primary Outcome Measures:
  • Rate and number of hospitalization for cardiovascular cause; Lipid profile [ Time Frame: 52week ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Biomarker : BNP, hsCRP, IL-6. TNF-α [ Time Frame: 52 week ] [ Designated as safety issue: Yes ]
  • Echocardiography : LVEF, E/A ratio, LVEDD, LVESD [ Time Frame: 52 week ] [ Designated as safety issue: Yes ]
  • Cardiac function evaluation (NYHA class distribution, 6-minute walk test) [ Time Frame: 52 week ] [ Designated as safety issue: Yes ]
  • Cardiovascular mortality [ Time Frame: 52 week ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 70
Study Start Date: July 2008
Study Completion Date: May 2014
Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
strong statin
Drug: pitavastatin
pitavastatin 4mg once daily
Active Comparator: 2
mild statin
Drug: pravastatin
pravastatin 10mg once daily


Ages Eligible for Study:   30 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients who accepted to enter the study by written informed consent
  2. Age ≥ 30 years
  3. LDL-cholesterol ≥ 70mg/dl
  4. Chronic heart failure of :

    • NYHA class II ~ III
    • Ischemic etiology
    • Left ventricular ejection fraction < 45%
    • Optimal therapy for chronic heart failure and stable clinical condition over the two weeks.

Exclusion Criteria:

  1. Patients who participated in other studies 3 months before enrollment
  2. Statin treatment within 2 months before enrollment
  3. Unstable decompensated heart failure at enrollment
  4. Acute coronary syndrome or cerebral vascular disease within 3 months before enrollment
  5. Coronary revascularization within 3 months before enrollment or planned at enrollment
  6. Any other serious disease or condition which might effect life expectancy such as malignancy, life-threatening infectious disease.
  7. Serum creatinine levels >= 3.0 mg/dl
  8. AST or AST levels >=2.5 times of ULN
  9. CK levels >=2 times of ULN
  10. Uncontrolled hypothyroidism : TSH level >= 2 times of ULN
  11. Pregnant or breastfeeding women, women who want to bearing
  12. Patients who might to be unsuitable by the decision of investigators
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00701285

Korea, Republic of
SEOUL St. Mary's Hospital
Seoul, Seocho-Ku, Korea, Republic of, 137-040
Sponsors and Collaborators
JW Pharmaceutical
Study Chair: Sang Hong Baek, MD, PhD KangNam St. Mary's Hospital
  More Information

No publications provided by JW Pharmaceutical

Additional publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: JW Pharmaceutical Identifier: NCT00701285     History of Changes
Other Study ID Numbers: CWP-PTV-703 
Study First Received: June 17, 2008
Last Updated: May 12, 2014
Health Authority: South Korea: Institutional Review Board

Keywords provided by JW Pharmaceutical:
heart failure

Additional relevant MeSH terms:
Heart Failure
Cardiovascular Diseases
Heart Diseases
Anticholesteremic Agents
Enzyme Inhibitors
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypolipidemic Agents
Lipid Regulating Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses processed this record on February 11, 2016